The vaccine NVX-CO 2373, has gained 89.3 per cent success in the third phase trial

The vaccine NVX-CO 2373, developed by the US biotech company Novavax to combat the corona virus, has gained 89.3 per cent success in the third phase trial conducted in the UK. It has also been found to be effective on new variants of the Corona found in Britain. The Serum Institute has now sought permission from DCGI to test it in India.

Let us tell you that Novavax is one of the six companies that the US government has involved in making a vaccine in its campaign of war against Corona. The campaign was named Operation Rap Speed ​​by the erstwhile Trump administration.

Novavax reported that two doses of her vaccine were 89.3 percent effective in controlling the epidemic. The results of a third phase trial conducted in Britain. Not only this, the vaccine is also very effective on the new form of corona found in Britain. Other results, however, state that it has been found to be less effective on the highly infectious virus found in South Africa.

Serum Institute, the world’s leading vaccine-producing company, has NovaWax Inca. Has asked for limited testing of the Covid-19 vaccine. Let me tell you, the world’s largest vaccination campaign is going on in India through the covicile vaccines being made in serum and by Kovaxin vaccines of Bharat Biotech. More than 1 million people have been vaccinated with Corona so far.

The vaccine NVX-CO 2373,  has gained 89.3 per cent success in the third phase trial
The vaccine NVX-CO 2373, has gained 89.3 per cent success in the third phase trial

Novavax reported that efforts were started earlier this month to create an effective vaccine against new forms of Corona. His vaccine is expected to be selected for use by the second quarter. American company CEO Stanley Erk said NVX-CO V2373 is expected to play an important role in tackling the epidemic worldwide and protecting public health. For this, the company is working closely with its partners, investors, regulators.